We systematically evaluated the clinical efficacy of Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury by Meta-analysis system.Methods:Randomized controlled trials of oral Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury were collected by searching China National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD)，China Biology Medicine disc(CBMdisc) and PubMed databases.Meta-analysis was performed by RevMan 5.3 software.Results:A total of 9 pieces of literature were included，with a total of 1 674 patients.Meta-analysis showed that Fufang Yiganling Capsules was able to decrease the levels of Aspartate aminotransferase[MD=-14.78，95%CI(-21.36 to -8.21)，P<0.000 1]，Alanine aminotransferase[MD=-4.31,95%CI(-7.09 to -1.52)，P＝0.002] and Total bilirubin[MD=-1.31,95%CI(-3.44 to 0.83)，P＝0.001] significantly，thereby reducing the rate of liver injury[MD=0.37,95%CI(0.30 to 0.45)，P<0.000 01] significantly.Conclusion:Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury had definite curative effects.